Related Experiment Video
Updated: May 2, 2026

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
Disease 'activity', 'severity' and 'impact': interrelationships in COPD; is a measure of disease 'activity' the Holy
Richard I Carter1, Robert A Stockley
11Centre for Translational Inflammation Research, University of Birmingham Research Laboratories , Birmingham , United Kingdom.
Insights
New biomarkers are needed to measure chronic obstructive pulmonary disease (COPD) activity, as current measures of disease severity do not fully capture the overall disease process or progression.
Area of Science:
- Pulmonary Medicine
- Biomarker Discovery
- Chronic Obstructive Pulmonary Disease (COPD)
Background:
- Current measures of chronic obstructive pulmonary disease (COPD) 'severity' (e.g., FEV1) are insufficient to capture overall disease 'activity'.
- The relationship between disease 'activity', 'severity', and 'impact' in COPD is poorly understood.
- There is a need for new biomarkers that accurately reflect COPD disease 'activity' and progression.
Purpose of the Study:
- To explore the need for new measures of COPD disease 'activity'.
- To discuss the characteristics of an ideal biomarker for COPD disease 'activity', emphasizing temporal stability.
- To examine the relationship between markers of COPD disease 'activity', 'severity', and 'impact'.
Main Methods:
- Review and discussion of existing literature on COPD biomarkers.
- Analysis of available data to infer the stability and variability of COPD disease 'activity'.
- Conceptual exploration of how different disease markers relate to each other.
Main Results:
- Existing markers of COPD 'severity' offer a limited view of disease 'activity'.
- No current biomarkers conclusively link to COPD disease progression.
- The stability and variability of COPD disease 'activity' remain uncertain and require further investigation.
Conclusions:
- Developing stable biomarkers for COPD disease 'activity' is crucial for early therapeutic intervention assessment in clinical trials.
- Further research is needed to understand the variability of COPD disease 'activity'.
- Clarifying the interplay between COPD 'activity', 'severity', and 'impact' markers is essential for advancing COPD understanding and treatment.
Abstract:
It is increasingly recognised that new measures of disease 'activity' for COPD are required, however the relationship between markers of disease 'activity', 'severity' and 'impact' though closely linked, is poorly understood. Additionally, while change in markers of disease 'severity' (e.g. change in FEV1) may be considered a marker of disease 'activity', these quantify a single aspect of disease 'activity' in COPD rather than measuring the overall disease process and this has stimulated the search for new biomarkers of COPD that reflect the 'activity' of the disease process. The ideal biomarker of disease 'activity' would be stable with respect to time since measurement at any time point would then relate to subsequent disease progression. This would allow the influence of a therapeutic intervention to be assessed early, facilitating both phase 2 and 3 clinical trials. Although a number of potential biomarkers of COPD disease 'activity' have been studied, to date none have been shown to conclusively relate to disease progression and the stability of underlying disease 'activity' therefore requires further consideration. Interestingly, while the variability of disease 'activity' of COPD is rarely mentioned in the current literature, and there is uncertainty whether 'activity' is constant or highly variable, there are clues from available data as discussed in the current article. Finally we consider how markers of disease 'activity', 'severity' and 'impact' may relate, which is of utmost importance in the ongoing search for new biomarkers in COPD and a greater understanding of the pathogenesis of the disease process.
More Related Videos
04:24Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations